N/A
Completed N=156
Retrospective Transverse Observational Study Of Previous Study (Initial Protocol, B1811030)
Survival Status at Day 30 After the Last Intake
Source: ClinicalTrials.gov NCT01840319 ↗
Enrolled (actual)
156
Serious AEs
—
Results posted
Jul 2014
Primary outcomePrimary: Percentage of Participants With Survival at 30 Days After Last Dose of Tigecycline — 80.60 percentage of participants
Summary
The goal of this retrospective observational study is to collect only status survival data 30 days after the last dose of treatment of patients included in the initial protocol WYETH 3074A1-4448 / B1811030. The purpose is to estimate the survival status, 30 days after the last intake of tigecycline to patients hospitalized in ICU and treated by tigecycline.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Survival at 30 Days After Last Dose of Tigecycline |
80.60 | — |
Eligibility Criteria
Inclusion Criteria
- All patients included in the previous study WYETH 3074A1-4448 then Pfizer B1811030 for which mortality status was not known at the closure of this previous study
Exclusion Criteria
- Patients who has withdrawn their consent for the study WYETH3074A1-4448 then Pfizer B1811030.
Data sourced from ClinicalTrials.gov (NCT01840319). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.